Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular prognostication in Ph-negative MPNs in 2022.

Hematology. American Society of Hematology. Education Program - 9 Dec 2022

Vannucchi Alessandro Maria, Guglielmelli Paola

Abstract excerpt

The application of genomic techniques, including cytogenetics and DNA sequencing, to decipher the molecular landscape of patients with myeloproliferative neoplasms (MPNs) has radically modified diagnostic approach and management through improved risk stratification. Three driver mutated genes (JAK2, MPL, CALR) are variably harbored by >80% of patients and associated with clinical characteristics, as well as major...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Mutation
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Prognosis

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 36485130
DOI: 10.1182/hematology.2022000339
PMCID: PMC9820187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular prognostication in Ph-negative MPNs in 2022.PMID 36485130Read ↗

Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.Semantic proximity Read ↗

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging DataSemantic proximity Read ↗

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.Semantic proximity Read ↗

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phaseSemantic proximity Read ↗

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.Semantic proximity Read ↗

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.Semantic proximity Read ↗

From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management.Semantic proximity Read ↗

Molecular profiling in MPN: who should have it and why?Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.Semantic proximity Read ↗

Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game.Semantic proximity Read ↗

Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing EraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.